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Release of the angiogenic cytokine vascular endothelial
growth factor (VEGF) from platelets: significance for
VEGF measurements and cancer biology
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Summary Vascular endothelial growth factor (VEGF) is a potent angiogenic factorwith a key role in several pathological processes, including
tumour vascularization. Our preliminary observations indicated higher VEGF concentrations in serum samples than in matched plasma
samples. We have now demonstrated that this difference is due to the presence of VEGF within platelets and its release upon their activation
during coagulation. In eight healthy volunteers, serum VEGF concentrations ranged from 76 to 854 pg mi-1 and were significantly higher (P<
0.01) than the matched citrated plasma VEGF concentrations, which ranged from < 9 to 42 pg mi-1. Using platelet-rich plasma, mean (s.d.)
platelet VEGF contents of 0.56 (0.36) pg of VEGF 10-6 platelets were found. Immunocytochemistry demonstrated the cytoplasmic presence
of VEGF within megakaryocytes and other cell types within the bone marrow. From examination of the effects of blood sample processing on
circulating VEGF concentrations, it is apparent that for accurate measurements, citrated plasma processed within 1 h of venepuncture should
be used. Serum is completely unsuitable. The presence of VEGF within platelets has implications for processes involving platelet and
endothelial cell interactions. e.g. wound healing, and in tumour metastasis, when platelets adhering to circulating tumour cells may release
VEGF at points of adhesion to endothelium, leading to hyperpermeability and extravasation of cells.
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Angiogenesis, the formation ofnew blood vessels from an existing
vasculature, is a complex multistep process involving degradation
of extracellular matrix proteins and activation, proliferation and
migration of endothelial cells and pericytes (Folkman and Shing,
1992; Diaz-Flores et al, 1994; Folkman, 1995). It plays a key role
in physiological processes involving neovascularization, such as
ovulation, placentation and embryogenesis, and is also central to
several pathological processes, such as tumour growth and metas-
tasis. Several factors have been identified that have angiogenic
activity, but one of the most potent and specific that has both
angiogenic and vasculogenic activity is vascular endothelial
growth factor (VEGF), also known as vascular permeability factor
(VPF) and vasculotropin (Dvorak et al, 1995; Ferrara et al, 1995;
Thomas 1996).
An endothelial-specific mitogen with additional activities on
endothelial cells, including induction of shape change, protease
production and migration (Dvorak et al, 1995; Ferrara et al, 1995;
Thomas, 1996), VEGF is a potent stimulator of angiogenesis in
both in vitro and in vivo models and induces microvascular hyper-
permeability. Originally identified as a secreted product oftumour
cells (Senger et al, 1983, 1986), it is now apparent that VEGF is
part of an emerging group of related molecules having approxi-
mately 15-25% homology at the amino acid level with the
platelet-derived growth factor family. Other recently identified
members include VEGF-related factor (VRF) or VEGF-B, VEGF-
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C (Grimmond et al, 1996; Joukov et al, 1996; Olofsson et al, 1996;
Paavonen et al, 1996) and placenta growth factor (Maglione et al,
1991; Hauser and Weich, 1993; Maglione et al, 1993). The active
form of VEGF is a homodimeric cytokine of molecular weight
34-46 kDa, the variation in size being due to alternative exon
splicing producing four different isoforms of 121, 165, 189 and
206 amino acids (monomeric size), the last three of which have
heparin binding activity (Houck et al, 1991; Tischer et al, 1991).
Many cell types produce VEGF (Dvorak et al, 1995; Ferrara et al,
1995; Thomas 1996), withVEGF165 being thepredominant soluble
isoform and VEGF189 and VEGF206 remaining almost completely
cell- or extracellular matrix-associated unless proteolytically
cleaved (Houck et al, 1992). Two high-affinity receptors forVEGF
have been identified and cloned, namely the fins-like tyrosine
kinase Flt-1 and the KDR (kinase insert domain-containing
receptor)/Flk-l tyrosine kinase (Shibuya et al, 1990; Matthews et
al, 1991; Terman et al, 1991; de Vries et al, 1992; Millauer et al,
1993). Found predominately on endothelial cells, VEGF receptors
have also been found on a limited number of other cell types,
including haematopoietic stem cells, megakaryocytes, platelets,
monocytes and ovarian tumour cells (Boocock et al, 1995; Katoh
et al, 1995; Barleon et al, 1996).
A key role for VEGF in tumour biology is supported by obser-
vations ofproduction by numerous tumour cell lines (Senger et al,
1983, 1986) and immunohistochemical demonstration in human
carcinomas ofseveral tissues, including breast (Brown et al, 1995;
Anan et al, 1996), lung (Mattern et al, 1996), liver (Warren et al,
1995), gastrointestinal tract (Brown et al, 1993b; Takahashi et al,
1995; Maeda et al, 1996), bladder (Brown et al, 1993a, O'Brien et
al, 1995), kidney (Brown et al, 1993a; Sato et al, 1994; Takahashi
et al, 1994) and ovary (Boocock et al, 1995; Abu-Jawdeh et al,
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Table 1 Collection and processing of blood samples for VEGF release
Tube type Processing
1. EDTA Full blood count
2. Plain Serum aliquoted
3. Citrate Plasma aliquoted
4. Citrate Thrombin added to plasma and serum aliquoted
5. Citrate Calcium added to whole blood and serum aliquoted
6. Citrate PRP prepared and cell counts performed
7. Citrate PRP prepared and cytospin preparations produced
8. Citrate PRP prepared, thrombin added and serum aliquoted
9. Citrate PRP prepared, calcium added and serum aliquoted
Thirty millilitres of venous blood was divided into the nine blood collection
tubes and processed as shown. Details of the methodology are provided in
the text.
1996). Correlations have been demonstrated between the degree of
vascularization and VEGF expression in breast and colon cancers
(Toi et al, 1993; Guidi et al, 1994; Toi et al, 1994; Takahashi et al,
1995) and between VEGF expression and prognosis in breast,
gastric and bladder cancer (O'Brien et al, 1995). Use of neutral-
izing antibodies to VEGF or transfection with antisense VEGF
cDNA havebeen shown to resultin inhibition ofgrowth oftumour
cell lines in nude mice and inhibition ofmetastatic spread (Asano
et al, 1995; Warren et al, 1995; Claffey et al, 1996; Saleh et al,
1996). Serum concentrations of VEGF have been examined in
patients with arange ofcancers, withhigher serum levels ofVEGF
being apparent in some patients (Kondo et al, 1994; Ferrari and
Scagliotti, 1996; Takano et al, 1996; Dirix et al, 1997).
While investigating the use of circulating VEGF as a possible
prognostic indicator in an ongoing study of patients with breast
cancer, we made the preliminary observation ofhigher concentra-
tions of VEGF in serum samples than in matched plasma, which
our initial investigations indicated to be due to release of VEGF
from platelets (Banks et al, 1996). We reporthere the results ofour
further investigations, which clearly indicate the presence of
VEGF in megakaryocytes and its release from platelets, and make
recommendations regarding optimal handling of biological
samples for accurate measurement of VEGF. The biological
implications ofthe findings are discussed.
MATERIALS AND METHODS
VEGF release in blood samples
Venous blood samples were obtained from healthy male and
female volunteers aged between 21 and 56 years. All sampling had
been approved by the local ethics committee. Plastic (polypropy-
lene) blood collection tubes (Monovettes and Microtubes) were
purchased from Sarstedt (Leicester, UK) and glass collection tubes
(Vacutainers) from Becton Dickinson (Oxford, UK). From each of
eight volunteers, 30 ml of venous blood was taken and divided into
3-mi plastic blood collection tubes containing either EDTA (potas-
sium salt; 0.12-0.2% (w/v) final concentration), trisodium citrate
(0.31% (w/v) final concentration) or no anticoagulant and
processed as indicated in Table 1. Serum and platelet-free plasma
samples were prepared by centrifugation at 2000 g for 10 min and
platelet-rich plasma (PRP) by centrifugation at 180 g for 10 min
with removal of the upper 1 ml of plasma only. Calcium or
thrombin activation of appropriate samples was carried out by the
addition of calcium chloride solution (BDH, Poole, UK) or
thrombin solution (Diagnostic Reagents, Oxon, UK) to a final
concentration of 20 mm or 2-4 U ml-l, respectively, followed by
centrifugation at 2000g for 10 min once the sample had clotted.
All manipulations were carried out immediately at room tempera-
ture with final plasma and serum aliquots stored at -70°C until
analysis. A Technicon H2 system was used for haematological
counts and to assess the degree of contamination of platelet-rich
plasma by other cells.
Measurement of VEGF
Samples were assayed for VEGF using a commercially available
sandwich enzyme-linked immunosorbent assay (ELISA) obtained
from R & D Systems Europe (Abingdon, UK), which is specific
for VEGF, not detecting related molecules, such as PDGF or
placental growth factor. The sensitivity of the assay was
9.0 pg ml-' as quoted by the manufacturer. All samples were
assayed in duplicate. After the initial observations ofhigher levels
of VEGF in serum samples compared with matched plasma
samples, a preliminary evaluation of the assay was carried out
assessing recovery and parallelity using a serum and an EDTA
plasma sample from a normal volunteer and an EDTA plasma
Table 2 VEGF concentrations in blood samples from eight healthy volunteers prepared as described in Table 1
Sample type and VEGF concentration (pg ml-')
Donor (2) Serum (3) Citrated plasma (4) Clotted citrated plasma (5) Clotted citrated blood (8) Thrombin-activated PRP (9) Ca activated PRP
E 351 ±9 42±1 27±0 278±34 160±3 80±1
F 346±1 11 ±6 19±2 327±8 161 ±1 98±2
G 854±8 22±5 18±2 372±16 505±17 369±7
H 109±3 13±1 29±7 85±3 54±1 28±4
1 76±6 15±0 20±7 56±7 41 ±3 32±2
J 202±4 <9 32±2 131 ±3 124±3 113±11
K 213±6 24±1 31 ±1 222±8 102±16 89±9
L 125±3 28±8 43±5 112± 1 38±0 34±3
PRP, platelet-rich plasma.
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sample from a patient with advanced cancer. Recombinant human
VEGF (R & D Systems Europe) was added to the samples (spiked)
to produce theoretical increases in VEGF concentration of
135 pg ml-1 and 1300 pg ml', the samples were diluted with assay
buffer and analysed for VEGF.
VEGF assay and Western blot analysis of platelet
concentrates
Platelets were prepared from a 7-day-old platelet concentrate
(prepared from platelet-rich plasma) obtained from the
Blood Transfusion Service. The platelet suspension (155 ml,
1.542 x 1012 plts 1-1, 0.28 x 109 WBC 1-l) was centrifuged at 2000 g
for 10 min at200C, the supernatant removed and assayed forVEGF
and the platelet pellet washed 2x with Tris buffered saline (50 mm
Tris-HCl, 150 mm sodium chloride, pH 7.4; TBS) containing 5 mM
glucose and 0.129 M sodium citrate. The platelet pellet was then
resuspended in 1 ml ofTBS containing 5 mm glucose and an excess
ofthrombin (320 U) added to ensure maximum release. After acti-
vation, the releasate was assayed for VEGF. For Western blotting
analysis, supernatant from stored platelets diluted with an equal
volume ofphosphate-buffered saline (PBS) and containing approx-
imately 100 ng of VEGF as measured by immunoassay was incu-
bated for 1 h at 40C with 1 ml of heparin sepharose (Pharmacia).
After incubation, the heparin sepharose was collected by centrifu-
gation, washed once with PBS and twice with PBS containing
0.5 M sodium chloride, resuspended in 200 ul of Laemmli elec-
trophoresis sample buffer containing 2% (w/v) sodium dodecyl
sulphate (SDS) and 5% v/v 2-mercaptoethanol, boiled for 4 min
and 75 ul per lane was electrophoresed on a 12% SDS-polyacry-
lamide gel (SDS-PAGE). After electrophoresis, the gel was elec-
troblotted onto nitrocellulose membranes (Hybond C Super;
Amersham, Little Chalfont, UK). Blots were blocked with
TBS/0.1% (v/v) Tween 20 (TBS-T) containing 10% (w/v) dried
skimmed milk, and VEGF was detected by sequential incubation
with a polyclonal rabbit antibody to VEGF, raised against the first
20 N-terminal amino acids of VEGF (Santa Cruz Biotechnology;
purchased from Autogen Bioclear, Devizes, UK) at 1 gg ml-1,
biotinylated sheep anti-rabbit immunoglobulins (Dako, UK) at
1:1000 dilution and peroxidase-conjugated streptavidin (Dako) at
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Figure 1 Circulating platelet number vs serum VEGF
eight normal donors. Clotted non-coagulated blood (0)
blood (0)
1:3000. Blots were developed using enhanced chemiluminescence
(ECL) reagents (Amersham, UK) with subsequent detection of
light emitted using XAR5 film (Kodak). Washing between steps
was carried out using TBS-T and all antibodies were diluted in
TBS-T containing 1% (w/v) dried skimmed milk. Fifty ng of
recombinant human VEGF (Peprotech, London, UK) was elec-
trophoresed as a positive control and molecular sizes of protein
bands were determined by parallel electrophoresis of biotinylated
molecular weight markers (Biorad, Hemel Hempstead, UK). Non-
specific binding of antibodies was determined by parallel incuba-
tion ofan identical blot with an irrelevant primary antibody in place
of the rabbit anti-VEGF. The anti-VEGF antibody specifically
reacts with VEGF and does not detect related molecules, such as
PDGF, placental growth factor, VEGF-B or VEGF-C (information
supplied by the manufacturer).
Immunocytochemistry
Platelet cytospins and normal bone marrow smears were air dried
and fixed in acetone for 5 min. Paraffin-embedded sections of a
trephine biopsy from a patient with idiopathic thrombocytopenia
purpura were dewaxed in xylene and subsequently rehydrated by
passage through alcohols to water. Specimens were then incubated
with 20% (v/v) normal goat seruminTBS for5 minbefore addition
of rabbit anti-VEGF (raised against the first 20 N-terminal amino
acids; Santa Cruz Biotechnology) at 2.5 jig ml-' in TBS/0.1% (w/v)
human serum albumin/0.1% (w/v) sodium azide. Endogenous
avidin-biotin binding sites were blocked using the avidin-biotin
blocking kit (Vector). After 1 h, specimens were washed in TBS
and incubated in biotinylated goat anti-rabbit immunoglobulins
(Vector) at 2.5 gg ml-' for 30 min. Labelling was visualized using a
Vectastain avidin-biotin alkaline phosphatase detection system
with Vector Red substrate (Vector) according to standard protocols.
Specimens were stained with haematoxylin for 1 min and mounted
or dehydrated and mounted as appropriate. Specificity controls
included omission of the primary antibody, use of an irrelevant
primary antibody and prior overnight adsorption of the primary
antibody with control VEGF peptide at 25 jg ml-1 (Santa Cruz
Biotechnology).
Determination of optimal sample processing for assay
of circulating VEGF
In order to study the effect of sample-handling time and anticoag-
ulant on VEGF levels in blood, 35 ml of venous blood was taken
from each of four volunteers and divided into 16 1.3-ml plastic
microtubes (Sarstedt) containing either EDTA (potassium salt),
lithium heparin, trisodium citrate or no anticoagulant (four of
each). Blood was also added to one each of a 3-ml plastic EDTA
tube, a 3-mlplastic citrate tube, a 3-ml glass citrate tube and a4-ml
glass EDTA tube. Serum and plasma were then prepared from one
8 ° ofeach type oftube by centrifuging at 2000g for 10 min, immedi-
ately and at 30 min, 1 h (largerplastic and glass tubes), 2 h and 4 h
after blood sampling. Serum and plasma samples were aliquoted
and stored at -70°C until analysis. In light of the results, further
300 350 blood samples were taken from four additional volunteers into
glass citrate and EDTA tubes and plastic EDTA tubes and plasma
prepared at 30 min and 1 h after collection. In addition, plasma
was prepared from blood samples 1 h after collection (matched
and clotted citrated glass citrate and EDTAtubes) from fivepatients with breast cancer
and stored at-700C until analysed.
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Figure 2 Theoretical VEGF production by platelets (serum and platelet-rich
plasma samples from eight normal donors)
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Figure 3 Western blotting of platelet supernatant (a and b) and
recombinant VEGF (c and d) by 12% SDS-PAGE under reducing conditions
using rabbit anti-VEGF as the primary antibody (a and c). the corresponding
negative controls (b and d) using an irrelevant rabbit primary antibody are
shown
Statistical analyses
Comparison ofthe effects ofdifferent types ofsample-handling on
VEGF concentration was carried out using one-way analysis of
variance (ANOVA) followed by modified t-test with Bonferroni
correction on those groups showing significant changes by
ANOVA, using the statistical package SPSS-PC.
RESULTS
Assessment of VEGF recovery in serum and plasma
samples and parallelity with the standard curve
Recoveries ofVEGF in the serum and plasma samples tested were
similar ranging from 94.1% to 112.6% with the lower spike and
from 106.1% to 119.7% with the higher spike. Similar recoveries
were also obtained with citrated plasma samples. Serial dilutions
of the spiked plasma and serum samples diluted out in parallel to
the standard curve (data not shown). Coefficients of variation of
samples assayed in duplicate were generally less than 5%.
VEGF release in blood samples
The VEGFconcentrations oftheblood samples fromtheeightvolun-
teers after the various treatments are shown in Table 2. Values have
been corrected for the dilution effect ofthe citrate anticoagulant and
thrombin addition when appropriate, taking into account the haemat-
ocrit, i.e. assuming the citrate partitions into the liquid phase.
Haematological analysis of the platelet-rich preparations showed
them to be 99-100% pure. Serum VEGF concentrations ranged from
76 to 854 pg ml-' and were significantly higher (P < 0.01) than the
matched citrated plasma VEGF concentrations, which ranged from
C
Figure 4 Immunostaining (red colour) of a bone marrow biopsy (A and B;
x 320) and a megakaryocyte from a bone marrow smear (C; x 1000) using a
rabbit anti-VEGF antibody (A and C) or irrelevant rabbit immunoglobulin (B)
< 9 to 42 pg ml-'. Clotting ofthe platelet-free plasma produced little
change (range 18-43 pg ml-1). However, clotting of PRP with
thrombin resulted in higher VEGF levels of 38-505 pg ml-',
which were significantly correlated with serum values (rs = 0.88,
P = 0.004), and clotting of citrated whole blood by recalcification
resulted in VEGF concentrations of56-372 pg ml-', which were also
significantly correlated with serum values (rs= 0.98, P<0.001).
Neither serum VEGF nor clotted citrate blood VEGF levels were
significantly correlated with any haematological parameter exam-
ined, just failing however to achieve a significant correlation with
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Figure 5 VEGF concentrations of plasma and serum samples from four healthy volunteers (A-D). The different types of anticoagulant are as indicated with the
time between venepuncture and sample processing indicated in hours (0-4). Bars show the standard deviations and asterisks indicate the results that are
statistically significantly different from the zero time point for each anticoagulant (*P < 0.05, **P < 0.01, ***P < 0.001)
platelet number [rs = 0.62 (P = 0.1) and 0.71 (P = 0.07) respectively;
Figure 1]. As a test ofthe hypothesis that platelets are a major source
of the elevated VEGF in serum samples, the VEGF concentrations
found after activation of PRP were calculated in terms of the
number ofplatelets present, and a similar calculation was performed
for the directly prepared serum samples. A significant correlation
(r = 0.95, P < 0.001) was found between the theoretical platelet-
derived VEGF in serum and PRP after platelet activation (Figure 2)
with mean (s.d.) values of 0.64 (0.41) and 0.56 (0.36) pg per 106
platelets respectively.
VEGF assay and Western blot analysis of platelet
concentrates
In the releasate of the thrombin-activated platelet concentrate
(containing 240 x 109 platelets), a total of 27 ng of VEGF was
detected by immunoassay, which was approximately 20% of that
expected on the basis of the above theoretical platelet-derived
VEGF concentrations found with PRP and serum. Assay of the
cell-free supernatant (155 ml) from the apheresis bag showed
VEGF to be present at a concentration of892 pg ml', representing
a further 138 ng of VEGF in total. Assuming this to be platelet-
derived, the total VEGF content of 165 ng represents a theoretical
platelet VEGF content of 0.69 pg per 106 platelets, a value similar
to those found using serum and PRP. Using Western blotting, a
single band of approximately 25 kDa was seen in the platelet
supematant (Figure 3) compared with a band of approximately
22 kDa for the non-glycosylated recombinant VEGF. No bands
were seen in the non-specific controls.
Immunocytochemistry
No positive staining for VEGF was observed for the platelet
cytospins. However, using the bone marrow samples, megakaryo-
cytes stained positively for VEGF with a granular cytoplasmic
appearance. Heterogeneous staining of some other cells, including
some myeloid cells and stromal elements, was seen but cells ofthe
erythroid lineage generally appeared to be negative (Figure 4). No
positive labelling of cells was seen with omission of the primary
antibody, replacement of the primary antibody with an irrelevant
rabbit antibody or after prior incubation of the anti-VEGF anti-
body with control VEGF peptide.
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Figure 6 A comparison of VEGF concentrations of plasma prepared with EDTA and citrate as anticoagulant in either plastic or glass tubes processed at 0.5
and 1 h post venepuncture. P, plastic, G, glass
Determination of optimal sample processing for
immunoassay of circulating VEGF
The effects of different anticoagulants and time before sample
processing for four healthy volunteers are shown in Figure 5.
Interindividual differences exist with significant increases in
VEGF concentration occurring with increasing time before sample
handling for clotted samples, and EDTA anticoagulated samples
in two people. No significant change with time was seen in
heparinized samples and a significant increase was seen in citrated
plasma levels in only one individual and then only after 2 h. Using
the 1 h time point as a comparison for each individual and exam-
ining the effects of anticoagulants relative to the citrate, which
should be expected to have minimal effect on platelet activation,
three of the four volunteers had significantly higher serum VEGF
concentrations (Figure SB, P < 0.01; Figure SC, P < 0.0001;
Figure SD, P < 0.001). EDTA and heparinized plasma VEGF
concentrations were significantly higher in one volunteer (Figure
SC, P < 0.0001 and P < 0.001 respectively) although EDTA
plasma VEGF concentrations in one further volunteer (Figure 5A)
were higher than those ofthe citrate sample butjust failed to reach
statistical significance because ofthe relatively high standard devi-
ation of the citrate VEGF sample at this time point in this volun-
teer (although being significantly higher at 30 min and 1 h).
The initial comparison of glass and plastic citrate and EDTA
tubes at 1 h showed no significant difference between glass and
plastic tubes for VEGF concentrations in citrated plasma.
However, the use ofglass EDTA tubes rather than plastic appeared
to minimize any increase in VEGF in three of the individuals.
When this was investigated further in four more individuals, with
VEGF concentrations in EDTA plasma from plastic and glass
tubes being compared with VEGF concentrations in citrated
plasma using glass tubes (samples processed at 30 min and 1 h
post-venepuncture), no difference was seen with regard to time
(Figure 6). However, using the 1-hour time point for comparison
purposes, the use of plastic EDTA tubes resulted in significantly
higher VEGF concentrations in all four individuals (P < 0.05 or
P < 0.01), whereas the use of glass EDTA tubes produced a result
significantly higher than that of citrated plasma in only two of the
four individuals.
When the VEGF concentrations of the matched citrate and
EDTA plasma samples (glass tubes) from the eight healthy volun-
teers were examined, together with those from five patients with
breast cancer, VEGF concentrations of <9-61 pg ml-' and
< 9-149 pg ml-', respectively, were found (mean ± s.d. of
27.0 ± 14.0 and 55.2 ± 39.6 respectively). The differences between
the two types of sample was statistically significant (P = 0.004),
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although the magnitude of the difference varied considerably
between individuals (from 0 to 88 pg ml-').
DISCUSSSION
Angiogenesis is important in both physiological and pathological
processes and the pivotal role of VEGF in angiogenesis and
vasculogenesis is clearly illustrated by the abnormality of blood
vessel development and embryonic lethality resulting from the loss
of even a single VEGF allele (Carmeliet et al, 1996; Ferrara et al,
1996). The regulation of the release of such a cytokine is obviously
critical, and the finding here that platelets carry a readily available
store ofVEGF has implications for early events in several processes
involving platelet-endothelial cell interactions, such as wound
healing, atherosclerosis and tumour metastasis. Platelets have been
implicated in tumour metastasis after observations of circulating
tumour cells forming aggregates with platelets, decreased
metastatic spread of tumour cells in thrombocytopenic mice
compared with normal animals or after treatments that decrease
platelet-tumour cell interactions and additionally the procoagulant
activity of many tumours leading to activation of platelets (Blood
and Zetter, 1990). Clearly the relevance ofplatelet-derived VEGF is
dependent on its local release and the number of platelets involved
and the overall balance with other platelet-derived angiogenic or
anti-angiogenic factors, such as platelet-derived endothelial cell
growth factor (thymidine phosphorylase), transforming growth
factor-5 (TGF-1), interleukin 1 (IL-1) and platelet activating factor-
4 (Harrison and Cramer, 1993).
The results here clearly show that the elevated levels of VEGF
in serum are as a result of its release from platelets during the clot-
ting process. Although initially conceivable that matrix effects of
serum and plasma or release of protein-sequestered VEGF by
protease release during coagulation could account for such effects,
the significant correlations between VEGF concentrations of
serum and clotted platelet-rich plasma but not platelet-free plasma
and those between the theoretical platelet-derived VEGF of serum
and platelet-rich plasma would support a platelet-derived source of
VEGF. Although platelet numberjust failed to reach a statistically
significant correlation with serum VEGF concentration, this is
probably explained by the interindividual variation in platelet
VEGF content as exemplified in Figure 2. Such a wide interindi-
vidual variability in cellular production of cytokines is not unex-
pected, also being the case, for example, for platelet content of
TGF-,B (Jiang et al, 1995). Using immunoassay and Western blot-
ting, the presence of VEGF in platelets was also confirmed by the
detection ofVEGF in supernatant from purified platelets after acti-
vation or prolonged storage, and its presence in megakaryocytes
demonstrated immunocytochemically. These results have implica-
tions for sample-handling if accurate VEGF measurements are to
be made. The material of choice would be citrated plasma
processed within 1 h of venepuncture, although heparinized
samples may represent a possible alternative and, although not
explored here, the addition of inhibitors of platelet degranulation
to the blood collection tubes may also be a consideration.
Although similar results were obtained for EDTA plasma and
citrated plasma in some cases, marked interindividual differences
exist, with significant elevations being seen in some individuals,
presumably because of differing degrees of platelet activation by
EDTA, which were less marked if glass tubes were used. The
reason for higher levels of VEGF in one EDTA sample compared
with the corresponding serum sample (Figure 5), which would be
assumed to contain the maximum level of platelet-derived VEGF
after platelet activation, is unclear but may reflect release from
other cells (e.g. monocytes) or release from a calcium-dependent
sequestration, for example a binding protein. Clearly serum is
totally unsuitable, with results having the potential to be markedly
influenced by platelet number and VEGF content. To date, only a
small number of studies have been carried out measuring circu-
lating VEGF concentrations and all have used serum samples
(Kondo et al, 1994; Baker et al, 1995; Hanatani et al, 1995; Ferrari
and Scagliotti, 1996; Takano et al, 1996; Watanabe et al, 1996;
Dirix et al, 1997; Lyall et al, 1997). Additional factors to be
considered when measuring VEGF in clinical samples should
include the specificity of the antibodies used in the assay and the
possible presence and effect of binding of VEGF to heparin-like
molecules, soluble receptors (Kendall and Thomas, 1993;
Boocock et al, 1995) and a2-macroglobulin (Soker et al, 1993).
The question of release of VEGF from platelet concentrates
during storage and its biological significance should be addressed.
Clearly, in the platelet concentrate sample examined here, signifi-
cant amounts of VEGF were present in the fluid phase after 7 days
storage. However, whether such release ofVEGF occurs within the
normal shelf-life of such concentrates and whether it is biologi-
cally active remains to be determined. Contaminating cytokines,
such as TNF-a, IL-1, IL-8 and IL-6, have been described in
platelet concentrates prepared from platelet-rich plasma and impli-
cated in transfusion reactions (Muylle et al, 1993; Stack and
Snyder, 1994) although thought to be derived from contaminating
white blood cells, such as monocytes, and significantly reduced
when prefiltered (Muylle and Peetermans, 1994; Aye et al, 1995).
A reduction in adverse reactions was also seen when platelet
concentrates derived from buffy coats were used (Oksanen et al,
1994), and studies have reported that white cell contamination in
such preparations is low and cytokine contamination is rare (Flegel
et al, 1995; Kluter et al, 1995).
Using immunohistochemical techniques, VEGF appears to
be present in megakaryocytes, with labelling being granular in
appearance. The inability to detect VEGF in platelets by light
microscopy was to be expected, given that the theoretical platelet-
derived VEGF amounts to approximately five molecules per cell.
The immunocytochemical demonstration of VEGF in megakary-
ocytes would not in itself be conclusive proofof synthesis by these
cells as endocytic pathways for proteins, such as albumin and IgG,
have been demonstrated (Harrison and Cramer, 1993). However,
while this study was in progress, a recent report has described the
presence of mRNA for VEGF in platelets and megakaryocytes
(Katoh et al, 1995). Ultrastructural and release studies are needed
to demonstrate whether the VEGF released by platelets Iis
contained within cytoplasmic granules or is localized to the
membranes, as is the case for IL-I (Hawrylowicz et al, 1989).
The presence of mRNA for VEGF has also been described in T
lymphocytes (Freeman et al, 1995), CD34+ cells and monocytes
(Katoh et al, 1995), with mRNA for the KDR and Flt-1 genes
encoding VEGF receptors also present in CD34+ cells, megakary-
ocytes and platelets (Katoh et al, 1995). These results support the
immunohistochemical demonstration here ofVEGF protein within
several cell types of the bone marrow. The role of VEGF within
the bone marrow is not clear, but the simultaneous presence of
VEGF and its receptors on several haematopoietic cell types may
indicate an autocrine or paracrine function in regulating growth or
differentiation of these cells, in addition to the regulation of
marrow endothelial cells. In further support of this, VEGF was
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found to enhance colony formation by mature subsets of granulo-
cyte-macrophage and erythroid progenitor cells stimulated with a
colony-stimulating factor but inhibited colony formation by more
immature subsets of progenitors. In single-cell assays, these
effects were absent or reduced implying both direct and indirect
actions of VEGF (Broxmeyer et al, 1995). VEGF also markedly
suppressed apoptotic cell death of normal human haematopoietic
stem cells or leukaemic cell lines after gamma-ray irradiation
(Katoh et al, 1995), supporting a potential role in survival and
maintenance ofthese cells.
Our observations suggest additional possible mechanisms for
the role of VEGF in cancer biology and prognosis. The adherence
ofcirculating tumour cells to platelets may result in platelet activa-
tion and release ofVEGF. This may result in increased endothelial
permeability, allowing cellular extravasation, and local release of
VEGF may stimulate neovascularization.
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NOTE ADDED IN PROOF
The production and release ofVEGF by platelets has been demon-
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